Zorvolex is tough sledding to say the least...actually sailing up river without comparative data, but you all know this. However, at least Zorvolex has a market of size to go after. Think about how much Indo.. Is actually written in the US. It's not very darn much...gout! That about covers it! And it will have even a tougher sell vs existing generics without comparative AE data.
The message I keep getting when asking about the future launch of "T" is real simple, if national/local sales of Zorvolex don't exponentially increase in Q3 no one will ever need be concerned with a future launch of "T". Clear enough
I don't think it's going to launch due to the fact that physicians and staff think Zorvoex is a joke. A drug that's 20 years old, with a higher co-pay and a lame management team can't pull another launch off. The pipeline is all COX-2 products. Think of another product using the "matrix technology" that patients will benefit from.
Why anyone currently trying to generate significant growth with Zorvolex is at all excited about T, is a mind rattler to me. This is a non-starter